GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Shiller PE Ratio

APVO (Aptevo Therapeutics) Shiller PE Ratio : (As of Apr. 11, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aptevo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Aptevo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Shiller PE Ratio Chart

Aptevo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptevo Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptevo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Aptevo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Shiller PE Ratio falls into.


;
;

Aptevo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aptevo Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Aptevo Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-4.328/133.1571*133.1571
=-4.328

Current CPI (Dec. 2024) = 133.1571.

Aptevo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.545 99.621 -0.728
201506 -0.876 100.684 -1.159
201509 -0.627 100.392 -0.832
201512 -0.885 99.792 -1.181
201603 -0.638 100.470 -0.846
201606 -0.635 101.688 -0.832
201609 -80,789.414 101.861 -105,611.412
201612 -16,812.148 101.863 -21,977.199
201703 -10,682.062 102.862 -13,828.135
201706 -11,979.657 103.349 -15,434.836
201709 40,284.043 104.136 51,510.783
201712 -10,306.230 104.011 -13,194.243
201803 -14,079.268 105.290 -17,805.712
201806 -13,223.340 106.317 -16,561.650
201809 -12,637.827 106.507 -15,800.099
201812 -14,128.000 105.998 -17,747.932
201903 -12,437.920 107.251 -15,442.328
201906 -6,739.920 108.070 -8,304.547
201909 -3,500.200 108.329 -4,302.401
201912 -3,874.640 108.420 -4,758.673
202003 1,448.920 108.902 1,771.638
202006 -3,418.800 108.767 -4,185.426
202009 -3,418.800 109.815 -4,145.498
202012 -3,125.760 109.897 -3,787.345
202103 -2,669.920 111.754 -3,181.251
202106 -2,849.000 114.631 -3,309.430
202109 -2,328.040 115.734 -2,678.506
202112 -2,067.560 117.630 -2,340.487
202203 -2,523.400 121.301 -2,770.040
202206 9,084.240 125.017 9,675.748
202209 -2,442.000 125.227 -2,596.652
202212 -1,546.600 125.222 -1,644.608
202303 643.060 127.348 672.395
202306 -1,996.150 128.729 -2,064.820
202309 -819.920 129.860 -840.741
202312 -493.644 129.419 -507.901
202403 -368.150 131.776 -372.008
202406 -2,718.760 132.554 -2,731.134
202409 -17.760 133.029 -17.777
202412 -4.328 133.157 -4.328

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aptevo Therapeutics  (NAS:APVO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aptevo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121